In ADHD Play, Pfizer Inks $700M Deal For NextWave Pharma

Law360, New York (October 22, 2012, 3:47 PM EDT) -- In a wager that reflects spiking rates of childhood behavioral ailments, Pfizer Inc. said Monday it will pay up to $700 million for NextWave Pharmaceuticals Inc., which recently won regulatory approval of Quillivant XR, the first once-daily liquid treatment for attention deficit hyperactivity disorder.

The purchase price for the California-based company, which three weeks ago earned U.S. Food and Drug Administration backing for Quillivant, includes a $20 million option payment, a $255 million payment Pfizer will make when the deal closes and $425 million in incentive...
To view the full article, register now.